Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: Correlation with protein expression

American Journal of Clinical Pathology

Volumn 128, Issue 3, 2007, Pages 404-413

  Lamy, Pierre Jean ^a   Verjat, Thibault ^b   Servanton, Anne Claire ^a   Paye, Malik ^b   Leissner, Philippe ^b   Mougin, Bruno ^b  

^a CENTRE VAL D AURELLE   (France)

^b BIOMÉRIEUX   (France)

Author keywords

Breast cancer; ELISA; Molecular diagnostics; NASBA; Nucleic acid sequence based amplification; Plasminogen activator inhibitor 1; Prognostic factors; Quantitative PCR; Tumor marker; Urokinase plasminogen activator

Indexed keywords

CYCLOPHILIN B; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SELF-SUSTAINED SEQUENCE REPLICATION; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 34748921204     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/K4JAF2NMD5EJU67Y     Document Type: Article

References (63)

1. Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res. 1996;2:613-618.
2. Durand MK, Bodker JS, Christensen A, et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost. 2004;91:438-449.
3. Aguirre Ghiso JA, Alonso DF, Farias EF, et al. Deregulation of the signaling pathways controlling urokinase production: its relationship with the invasive phenotype. Eur J Biochem. 1999;263:295-304.
4. Nguyen DH, Catling AD, Webb DJ, et al. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol. 1999;146:149-164.
5. Janicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost. 1991;17:303-312.
6. Stephens RW, Brunner N, Janicke F, et al. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat. 1998;52:99-111.
7. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000;60:636-643.
8. Janicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst. 2001;93:913-920.
9. Zemzoum I, Kates RE, Ross JS, et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol. 2003;21:1022-1028.
10. Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002;94:116-128.
11. Foekens JA, Schmitt M, van Putten WL, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol. 1994;12:1648-1658.
12. Grondahl-Hansen J, Peters HA, van Putten WL, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res. 1995;1:1079-1087.
13. Eppenberger U, Kueng W, Schlaeppi JM, et al. Markers of tumor angiogenesis and proteolysis independently define high-and low-risk subsets of node-negative breast cancer patients. J Clin Oncol. 1998;16:3129-3136.
14. Kim SJ, Shiba E, Kobayashi T, et al. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res. 1998;4:177-182.
15. Kute TE, Grondahl-Hansen J, Shao SM, et al. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat. 1998;47:9-16.
16. Knoop A, Andreasen PA, Andersen JA, et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer. 1998;77:932-940.
17. Bouchet C, Hacene K, Martin PM, et al. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol. 1999;17:3048-3057.
18. Konecny G, Untch M, Arboleda J, et al. HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res. 2001;7:2448-2457.
19. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol. 2002;20:1000-1007.
20. Hansen S, Overgaard J, Rose C, et al. Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients. Br J Cancer. 2003;88:102-108.
21. de Cremoux P, Bieche I, Tran-Perennou C, et al. Interlaboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reaction. Endocr Relat Cancer. 2004;11:489-495.
22. Tong D, Schneeberger C, Czerwenka K, et al. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer. Clin Cancer Res. 1999;5:1497-1502.
23. Spyratos F, Bouchet C, Tozlu S, et al. Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer. Anticancer Res. 2002;22:2997-3003.
24. Castello R, Estelles A, Vazquez C, et al. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer. Clin Chem. 2002;48:1288-1295.
25. Deiman B, van Aarle P, Sillekens P. Characteristics and applications of nucleic acid sequence-based amplification (NASBA). Mol Biotechnol. 2002;20:163-179.
26. Lamy PJ, Verjat T, Paye M, et al. NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer. Clin Chem Lab Med. 2006;44:3-12.
27. Molina R, Barak V, van Dalen A, et al. Tumor markers in breast cancer: European Group on Tumor Markers recommendations. Tumour Biol. 2005;26:281-293.
28. Verjat T, Cerrato E, Jacobs M, et al. Multiparametric duplex real-time nucleic acid sequence-based amplification assay for mRNA profiling. Biotechniques. 2004;37:476-481.
29. de Baar MP, van Dooren MW, de Rooij E, et al. Single rapid real-time monitored isothermal RNA amplification assay for quantification of human immunodeficiency virus type 1 isolates from groups M, N, and O. J Clin Microbiol. 2001;39:1378-1384.
30. Polstra AM, Goudsmit J, Cornelissen M. Development of realtime NASBA assays with molecular beacon detection to quantify mRNA coding for HHV-8 lytic and latent genes. BMC Infect Dis. 2002;2:18. Available at http://www.biomedcentral.eom/1471-2334/2/18. Accessed September 4, 2002.
31. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
32. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-35.
33. Delacour H, Servonnet A, Perrot A, et al. ROC (receiver operating characteristics) curve: principles and application in biology [in French]. Ann Biol Clin (Paris). 2005;63:145-154.
34. Arens N, Gandhari M, Bleyl U, et al. In vitro suppression of urokinase plasminogen activator in breast cancer cells: a comparison of two antisense strategies. Int J Oncol. 2005;26:113-119.
35. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
36. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
37. Benraad TH, Geurts-Moespot J, Grondahl-Hansen J, et al. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Eur J Cancer. 1996;32:1371-1381.
38. Sweep CGJ, Geurts-Moespot J, Grebenschikov N, et al. External quality assessment of trans-European multicenter antigen determination (enzyme-linked immunosorbent assay) of urokinase plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer extracts. Br J Cancer. 1998;78:1434-1441.
39. Duffy MJ. New cancer markers. Ann Clin Biochem. 1989;26:379-387.
40. Spyratos F, Martin PM, Hacene K, et al. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst. 1992;84:1266-1272.
41. Foekens JA, Look MP, Peters HA, et al. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995;87:751-756.
42. Harbeck N, Kates RE, Look MP, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res. 2002;62:4617-4622.
43. Look M, van Putten W, Duffy M, et al. Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost. 2003;90:538-548.
44. Piccart MJ, Sotiriou C, Cardoso F. New data on chemotherapy in the adjuvant setting. Breast. 2003;12:373-378.
45. Harbeck N, Kates RE, Schmitt M, et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer. 2004;5:348-352.
46. Manders P, Tjan-Heijnen VC, Span PN, et al. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer. Thromb Haemost. 2004;91:514-521.
47. Grebenchtchikov N, Maguire TM, Riisbro R, et al. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol Rep. 2005;14:235-239.
48. Schmitt M, Sturmheit AS, Welk A, et al. Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA. Methods Mol Med. 2006;120:245-265.
49. 2- macroglobulin receptor in human breast carcinomas. Int J Cancer. 1996;66:441-452.
50. Ferrier CM, Witte HHD, Straatman H, et al. Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. Br J Cancer. 1999;79:1534-1541.
51. Ferrier CM, van Geloof WL, de Witte HH, et al. Epitopes of components of the plasminogen activation system are re-exposed in formalin-fixed paraffin sections by different retrieval techniques. J Histochem Cytochem. 1998;46:469-476.
52. Han B, Nakamura M, Mori I, et al. Urokinase-type plasminogen activator system and breast cancer. Oncol Rep. 2005;14:105-112.
53. Hewitt R, Danø K. Stromal cell expression of components of matrix-degrading protease systems in human cancer. Enzyme Protein. 1996;49:163-174.
54. Dano K, Behrendt N, et al. Plasminogen activation and cancer. Thromb Haemost. 2005;93:676-681.
55. Offersen BV, Nielsen BS, Hoyer-Hansen G, et al. The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol. 2003;163:1887-1899.
56. Dublin E, Hanby A, Patel NK, et al. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma: fibroblastic expression has strong associations with tumor pathology. Am J Pathol. 2000;157:1219-1227.
57. Dong-Le Bourhis X, Lambrecht V, Boilly B. Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells. Br J Cancer. 1998;77:396-403.
58. Pakneshan P, Tetu B, Rabbani SA. Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clin Cancer Res. 2004;10:3035-3041.
59. Xing RH, Rabbani SA. Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation. Int J Cancer. 1999;81:443-450.
60. Ma Z, Webb DJ, Jo M, et al. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci. 2001;114:3387-3396.
61. Shetty S, Idell S. Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro. Am J Physiol Lung Cell Mol Physiol. 2000;278:148-156.
62. Heaton JH, Dlakic WM, Gelehrter TD. Posttranscriptional regulation of PAI-1 gene expression. Thromb Haemost. 2003;89:959-966.
63. Leissner P, Verjat T, Bachelot T, et al. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer. 2006;6:216. Available at http://www.biomedcentral.eom/1471-2407/6/16. Accessed August 31, 2006.